» Articles » PMID: 6589637

A Species of Human Alpha Interferon That Lacks the Ability to Boost Human Natural Killer Activity

Overview
Specialty Science
Date 1984 Aug 1
PMID 6589637
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Most species of recombinant leukocyte interferons (IFN-alpha A, -alpha B, -alpha C, -alpha D, -alpha F, -alpha I, and -alpha K) were capable of boosting human natural killer (NK) activity after a 2-hr treatment of cells at a concentration of 1-80 units/ml. In contrast, recombinant human IFN-alpha J was found to be incapable of augmenting NK activity after exposure of cells for 2 hr to concentrations as high as 10,000 units/ml. This inability of IFN-alpha J to boost NK activity was not complete because, after exposure of cells to a high concentration of IFN-alpha J (10,000 units/ml) for 18 hr, boosting of cytolysis was observed. IFN-alpha J appeared to interact with receptors for IFN on NK cells since it was found to interfere with the boosting of NK activity by other species of IFN-alpha. In contrast to its deficient ability to augment NK activity, IFN-alpha J has potent antiviral and antiproliferative activities. Such extensive dissociation of these biological activities has not been observed previously with any other natural or recombinant IFN species. Thus, this IFN species may be useful for evaluating the relative importance of various biological activities on the therapeutic effects of IFN, for understanding structure-function relationships, and for determining the biochemical pathways related to the various biological effects of IFN.

Citing Articles

Interferon-α and its effects on cancer cell apoptosis.

Shi W, Yao X, Fu Y, Wang Y Oncol Lett. 2022; 24(1):235.

PMID: 35720476 PMC: 9185151. DOI: 10.3892/ol.2022.13355.


A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.

Miersch S, Kuruganti S, Walter M, Sidhu S Protein Eng Des Sel. 2017; 30(9):697-704.

PMID: 28981904 PMC: 5914384. DOI: 10.1093/protein/gzx048.


Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection.

Gibbert K, Joedicke J, Meryk A, Trilling M, Francois S, Duppach J PLoS Pathog. 2012; 8(8):e1002868.

PMID: 22912583 PMC: 3415439. DOI: 10.1371/journal.ppat.1002868.


Interferon-β inhibits toll-like receptor 9 processing in multiple sclerosis.

Balashov K, Aung L, Vaknin-Dembinsky A, Dhib-Jalbut S, Weiner H Ann Neurol. 2010; 68(6):899-906.

PMID: 21061396 PMC: 3058378. DOI: 10.1002/ana.22136.


Dissecting interferon-induced transcriptional programs in human peripheral blood cells.

Waddell S, Popper S, Rubins K, Griffiths M, Brown P, Levin M PLoS One. 2010; 5(3):e9753.

PMID: 20339534 PMC: 2842296. DOI: 10.1371/journal.pone.0009753.


References
1.
Herberman R, Ortaldo J, Bonnard G . Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature. 1979; 277(5693):221-3. DOI: 10.1038/277221a0. View

2.
Heron I, Hokland M, Berg K . 13 native human interferon-alpha species assessed for immunoregulatory properties. J Interferon Res. 1983; 3(2):231-9. DOI: 10.1089/jir.1983.3.231. View

3.
Evinger M, Maeda S, Pestka S . Recombinant human leukocyte interferon produced in bacteria has antiproliferative activity. J Biol Chem. 1981; 256(5):2113-4. View

4.
Timonen T, Ortaldo J, Herberman R . Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med. 1981; 153(3):569-82. PMC: 2186097. DOI: 10.1084/jem.153.3.569. View

5.
Staehelin T, Hobbs D, Kung H, Lai C, Pestka S . Purification and characterization of recombinant human leukocyte interferon (IFLrA) with monoclonal antibodies. J Biol Chem. 1981; 256(18):9750-4. View